{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T17:38:00Z","timestamp":1781199480954,"version":"3.54.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T00:00:00Z","timestamp":1692403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T00:00:00Z","timestamp":1692403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s10384-023-01020-8","type":"journal-article","created":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T02:01:46Z","timestamp":1692410506000},"page":"658-667","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Persistence of the carteolol hydrochloride\/latanoprost fixed-combination ophthalmic solution, compared with the other \u03b2-blocker\/prostanoid FP receptor agonist fixed-combination ophthalmic solutions"],"prefix":"10.1007","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8506-8503","authenticated-orcid":false,"given":"Kenji","family":"Kashiwagi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Ouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Shibasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Suginaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,19]]},"reference":[{"key":"1020_CR1","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s10384-018-0623-4","volume":"63","author":"Y Morizane","year":"2019","unstructured":"Morizane Y, Morimoto N, Fujiwara A, Kawasaki R, Yamashita H, Ogura Y, et al. Incidence and causes of visual impairment in Japan: the first nation-wide complete enumeration survey of newly certified visually impaired individuals. Jpn J Ophthalmol. 2019;63:26\u201333.","journal-title":"Jpn J Ophthalmol"},{"key":"1020_CR2","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.2014.3192","volume":"311","author":"RN Weinreb","year":"2014","unstructured":"Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014;311:1901\u201311.","journal-title":"JAMA"},{"key":"1020_CR3","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1016\/j.ophtha.2008.02.005","volume":"115","author":"A Heijl","year":"2008","unstructured":"Heijl A, Bengtsson B, Chauhan BC, Lieberman MF, Cunliffe I, Hyman L, et al. A comparison of visual field progression criteria of 3 major glaucoma trials in early manifest glaucoma trial patients. Ophthalmology. 2008;115:1557\u201365.","journal-title":"Ophthalmology"},{"key":"1020_CR4","doi-asserted-by":"crossref","unstructured":"Kiuchi Y, Inoue T, Shoji N, Nakamura M, Tanito M, Glaucoma Guideline Preparation Committee, Japan Glaucoma Society. The Japan Glaucoma Society guidelines for glaucoma 5th edition. Jpn J Ophthalmol. 2023;67:189\u2013254.","DOI":"10.1007\/s10384-022-00970-9"},{"key":"1020_CR5","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s10384-013-0284-2","volume":"58","author":"K Kashiwagi","year":"2014","unstructured":"Kashiwagi K, Furuya T. Persistence with topical glaucoma therapy among newly diagnosed Japanese patients. Jpn J Ophthalmol. 2014;58:68\u201374.","journal-title":"Jpn J Ophthalmol"},{"key":"1020_CR6","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1016\/j.ophtha.2007.03.042","volume":"114","author":"HA Quigley","year":"2007","unstructured":"Quigley HA, Friedman DS, Hahn SR. Evaluation of practice patterns for the care of open-angle glaucoma compared with claims data: the glaucoma adherence and persistency study. Ophthalmology. 2007;114:1599\u2013606.","journal-title":"Ophthalmology"},{"key":"1020_CR7","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.ophtha.2004.12.026","volume":"112","author":"AL Robin","year":"2005","unstructured":"Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology. 2005;112:863\u20138.","journal-title":"Ophthalmology"},{"key":"1020_CR8","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.ajo.2007.06.012","volume":"144","author":"AL Robin","year":"2007","unstructured":"Robin AL, Novack GD, Covert DW, Crockett RS, Marcic TS. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol. 2007;144:533\u201340.","journal-title":"Am J Ophthalmol"},{"key":"1020_CR9","doi-asserted-by":"publisher","first-page":"1000248","DOI":"10.4172\/2155-9570.1000248","volume":"3","author":"GF Schwartz","year":"2012","unstructured":"Schwartz GF, Burk C, Bennett T, Patel VD. Adherence and persistence with glaucoma therapy: brimonidine\/timolol versus dorzolamide\/timolol and various two-bottle combinations. J Clin Exp Ophthalmol. 2012;3:1000248.","journal-title":"J Clin Exp Ophthalmol."},{"key":"1020_CR10","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.2147\/PPA.S168921","volume":"12","author":"Y Hasebe","year":"2018","unstructured":"Hasebe Y, Kashiwagi K, Tsumura T, Suzuki Y, Yoshikawa K, Suzumura H, et al. Changes in adherence and associated factors among patients on newly introduced prostaglandin analog and timolol fixed-combination therapy. Patient Prefer Adherence. 2018;12:1567\u201377.","journal-title":"Patient Prefer Adherence"},{"key":"1020_CR11","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s10792-018-0820-7","volume":"39","author":"T Tsumura","year":"2019","unstructured":"Tsumura T, Kashiwagi K, Suzuki Y, Yoshikawa K, Suzumura H, Maeda T, et al. A nationwide survey of factors influencing adherence to ocular hypotensive eyedrops in Japan. Int Ophthalmol. 2019;39:375\u201383.","journal-title":"Int Ophthalmol"},{"key":"1020_CR12","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.ophtha.2019.10.022","volume":"127","author":"PA Newman-Casey","year":"2020","unstructured":"Newman-Casey PA, Niziol LM, Gillespie BW, Janz NK, Lichter PR, Musch DC. The association between medication adherence and visual field progression in the collaborative initial glaucoma treatment study. Ophthalmology. 2020;127:477\u201383.","journal-title":"Ophthalmology"},{"key":"1020_CR13","unstructured":"Takahashi M, Naitou T, Mizoue S, Kanno M, Suzumura H, Yoshikawa K. Questionnaire survey on use of glaucoma eyedrops: second report. J Eye. 2012;29:555\u201361 (in Japanese)."},{"key":"1020_CR14","unstructured":"Kikuchi S, Ouchi K. Mikeluna\u00ae combination ophthalmic solution, carteolol hydrochloride 2% \/latanoprost 0.005% fixed combination for glaucoma and ocular hypertension. Jpn J Ocul Pharmacol. 2017;31:28\u201333 (in Japanese)."},{"key":"1020_CR15","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12886-021-01813-w","volume":"21","author":"C Shirai","year":"2021","unstructured":"Shirai C, Matsuoka N, Nakazawa T. Comparison of adherence between fixed and unfixed topical combination glaucoma therapies using Japanese healthcare\/pharmacy claims database: a retrospective non-interventional cohort study. BMC Ophthalmol. 2021;21:52.","journal-title":"BMC Ophthalmol"},{"key":"1020_CR16","first-page":"373","volume":"9","author":"TJ Zimmerman","year":"1993","unstructured":"Zimmerman TJ. Topical ophthalmic beta blockers: a comparative review. J Cli Exp Ophthalmol. 1993;9:373\u201384.","journal-title":"J Cli Exp Ophthalmol."},{"key":"1020_CR17","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00417-021-05357-z","volume":"260","author":"A Kido","year":"2022","unstructured":"Kido A, Miyake M, Akagi T, Ikeda HO, Kameda T, Suda K, et al. Association between topical \u03b2-blocker use and asthma attacks in glaucoma patients with asthma: a cohort study using a claims database. Graefes Arch Clin Exp Ophthalmol. 2022;260:271\u201380.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1020_CR18","unstructured":"Ministry of Health, Labour and Welfare. Medical Facility Survey (as of June 2022). https:\/\/www.mhlw.go.jp\/toukei\/saikin\/hw\/iryosd\/m22\/dl\/is2206_01.pdf. Accessed 1 September 2022 (in Japanese)."},{"key":"1020_CR19","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.ajo.2005.04.051","volume":"140","author":"BL Nordstrom","year":"2005","unstructured":"Nordstrom BL, Friedman DS, Mozaffari E, Quigley HA, Walker AM. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol. 2005;140:598\u2013606.","journal-title":"Am J Ophthalmol"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-023-01020-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10384-023-01020-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-023-01020-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T06:17:54Z","timestamp":1700201874000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10384-023-01020-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,19]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["1020"],"URL":"https:\/\/doi.org\/10.1007\/s10384-023-01020-8","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,19]]},"assertion":[{"value":"15 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"K. Kashiwagi, Consulting fees (Otsuka, Novartis, Santen, Senju, Kowa); K. Ouchi, Employee (Otsuka); Y. Shibasaki, Employee (Otsuka); M. Suginaka, Employee (Otsuka).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}